Visiongain has released a new report titled Biobanks 2022-2032. Includes biobanks market segment profiles and forecasts by type (self-contained, partnership) market segment by application (regenerative medicine, life science research, clinical research) market segment by property, (national / regional, university, non-purpose for-profit, private) Market segment by sample type, (blood products, human tissues, nucleic acids, cell lines, biological fluids, other samples) Market segment by product and service, (equipment, consumables, services, software ) plus COVID-19 impact analysis and recovery model Analysis (“V”, “W”, “U”, “L” shaped), Profiles of Leading Companies, Region and Country.
The global biobanking market has been valued at $ 56.955 million in 2021 and is expected to grow at a CAGR of 4.67% during the forecast period 2022-2032.
Growing opportunities for IT companies in the biobank market
Biobanks work hard to allocate funding to IT companies as it is suitable for all biobank activities, from recruiting subjects to publishing research results. Key investment goals include sample management and an accessible channel for organizations and individuals. A growing area of interest is the use of common standards to provide access to clinical and experimental databases. If the ontologies are standardized correctly, this allows for a complete annotation of the example. For example, continuous and resource-intensive standardization of disease coding and sample categorization. Standardization will become a major bottleneck in the biobank if it is not completed in time. Scientific concern about interoperability between biobanks is also increasing around the world.
Download sample: https://www.visiongain.com/report/biobanking-market-2022/#download_sampe_div
How has COVID-19 had a significant negative impact on the biobank market?
Globally, the 2019 coronavirus (COVID-19) outbreak is having a significant influence on the social, political, economic and health systems of many nations around the world. There are several concomitant clinical concerns during a pandemic, from the urgent need to understand the biology of the disease to the need for optimal patient treatment and case prevention in the future. Research infrastructures, and in particular biobanks, have positioned themselves at the forefront of the numerous and distinct responses needed to COVID-19. There have been reports of initiatives to compile population-wide databases of COVID-19 patients, symptomatic carriers and members of the general public in the European Union (EU), Taiwan and elsewhere. An attempt to bring together clinically meaningful cohorts is also occurring in situations of scarce resources where some infrastructures were accessible and sustained over time. In many cases, this effort is connected to a management structure that is more open to sharing samples and data.
How will this relationship benefit you?
Visiongain’s 558 page report provides 357 tables and 309 charts / graphs. Our new study is suitable for anyone requiring in-depth business analysis of the global Biobanking market, along with a detailed analysis of market segments. Our new study will help you evaluate the global global and regional biobank market. Get the financial analysis of the general market and the different segments including type, process, upstream, downstream and company size and gain a higher market share. We believe there are strong opportunities in this fast growing biobank market. Find out how to use existing and future opportunities in this market to gain revenue benefits in the near future. In addition, the report will help you improve your strategic decision making, allowing you to frame growth strategies, strengthen the analysis of other market players and maximize the productivity of the company.
What are the current market drivers?
The rapidly developing field of biobanks allows for vast sources of human biological material and related data
The main objective of biobanks seems to be the knowledge of diseases and the creation of new therapies. Furthermore, although the goal of biobank research is to shed new light on the genetic basis of human diseases, another key goal is to provide a more automated and tailored approach to therapy. With the rapid growth of biobanks, it is now possible to collect vast deposits of non-human biological materials, including plants, animals and microorganisms, among others. The expansion of numerous biobanks and reporting and monitoring are expected to revolutionize research, enabling personalized medicine and other benefits.
More emphasis on genetic testing and precision medicine
Traditional therapies today often don’t work because they don’t take into account a person’s unique traits and genetic makeup. The search throughout history for more effective and accurate treatment has led to the creation of the scientific area known as “personalized medicine”. Personalized medicine has been recognized by the next generations of diagnoses and treatments as a consequence of the significant technical developments in this area. Although it has attracted a lot of attention lately, there are still significant obstacles hindering its application in clinical practice. The borders have recently come to light due to the COVID-19 pandemic. Precision and personalized medicine are transforming medical diagnosis and paving the way for comprehensive, patient-centered diagnostics.
Download sample: https://www.visiongain.com/report/biobanking-market-2022/#download_sampe_div
Where are the market opportunities?
Advancement in biomedical research and personalized treatment requires human biosamples
The development of personalized medicine and the discovery of biomarkers depend on human biosamples. Biobanks collect, store and distribute cells, blood, various biofluids and residual tissue samples from patients for scientific studies. Until recently, the market was very diverse, with biobanks targeting a particular market and typically not maintaining a comprehensive collection of experimental information for each sample. It needs an overhaul, which fortunately several exciting new companies are starting to provide. For the proper use of biological samples, associated data and downstream research, as well as for the biotech and pharmaceutical industries, biobanks are essential resources. The best biobank techniques are highly dependent on individuals and their interests. By exchanging information, using state-of-the-art technological solutions and complying with some of the latest standards, biobanks can reach their full potential.
Increasing focus on cell therapies
Patients can now receive treatment for a variety of aids that were previously incurable due to the development of the cell and gene therapy industry. As a result, pharmaceutical companies are spending a lot of money on research and development to develop new therapies, and many gene and cell therapy drugs are now in the early stages of development. Together with the substantial investment in research and development, the sector is expected to witness strong commercial growth. Emerging economies around the world offer a wide range of business opportunities for stakeholders.
Major players in the biobank market are AMS Biotechnology (Europe) Ltd., ASKION GmbH, Avantor, Inc., Azenta, Inc. (Azenta), Bay Biosciences LLC, Bioivt & Elevating Science, Boca Biolistics, CTI Biotech, Cureline Inc. , Firalis SA, Geneticist Inc., Hamilton Bonaduz AG, Isenet Biobanking, Merck & Co., Inc., ProteoGenex Inc., Qiagen NV, Stemcell Holdings, Inc., STEMCELL Technologies Inc., Thermo Fisher Scientific Inc., US Biolab Corp . Inc .. The major players operating in this market have adopted various strategies which include mergers and acquisitions, investments in research and development, collaborations, partnerships, regional business expansion and new product launches.
On May 5, 2022, Avantor, Inc., announced plans to combine its current distribution center with new manufacturing operations in Singapore to establish a new manufacturing and distribution hub.
On April 19, 2022, Applied Cells Inc. and STEMCELL Technologies Canada Inc. announced their partnership to develop a new high-performance cell separation solution that combines Applied Cells’ MARS® platform with STEMCELL’s EasySepTM Immunomagnetic Cell Separation Kits . Thanks to this collaboration, researchers around the world will be able to more effectively and automatically separate high-quality cells from a variety of sample types, including whole blood, bone marrow, apheresis products and dissociated tissue.
Avoid losing by staying informed – order our report now.
To find more Visiongain Pharmaceutical Research Reports, click on the following links:
Do you have any custom requirements we can help you with? Do you need a specific country, geographic region, market segment or company specific information? Contact us today, we can discuss your needs and see how we can help you: email@example.com
Visiongain is one of the fastest growing and most innovative independent market information providers around, the company publishes hundreds of them market research reports which each year adds to its extensive portfolio. These reports offer in-depth analysis across 18 industries around the world. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Gaining insight works across a wide range of verticals with many synergies. These markets include the automotive, aviation, chemical, information technology, defense, energy, food and beverage, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports offer tailored market information tailored to your business needs.
PR at Visiongain Reports Limited
Phone: +44 0207 336 6100